Leverage Proven Viral Vector Expertise, Skip the Trial and Error
Discover the difference with a dedicated and experienced CDMO partner for viral vectors
Whether you are advancing a pre-IND novel cell or gene therapy or scaling toward commercialization, an experienced viral vector CDMO can make the difference between program delays and a smooth path to clinic and beyond.
With over 50 INDs supported and 7+ pre-commercial programs, FUJIFILM Biotechnologies’ viral vector CDMO brings the expertise and technical knowhow to design scalable processes, reduce manufacturing risk, and navigate the complexities associated with viral vector production. Allowing your cell or gene therapy to move forward from early development through clinical and commercial production.
AAV, lentivirus, adenovirus & more
Process and analytical development
GMP manufacturing
Fill / Finish
Overcoming Challenges and Accelerating the Path to Patients
Few challenges in cell and gene therapy development are as complex as viral vector production. In this video interview, learn how an experienced CDMO aligns platforms, expertise, and scale for each program’s unique needs, leveraging their expertise to provide optimized processes, help navigate regulatory hurdles, and deliver tailored solutions for cell and gene therapies.
Efficient and Effective Delivery of AAV Therapies to Patients via Candidate Screening and Feasibility Studies
Candidate screening and feasibility studies play a critical role in advancing AAV-based gene therapies. Streamlined processes maximize efficiency and quality throughout the development cycle and can help support early development milestone decisions, leading to successful drug manufacturing and commercialization. Discover more in this white paper.
DownloadViral Vector Manufacturing Simplified: A Sponsor’s Guide to Smarter CDMO Partnerships
For cell and gene therapies, the path from bench to patient is complex, costly, and filled with risk. Discover practical insights to de-risk development and maximize CDMO partner value, turning your molecule’s complexity into competitive advantage.
DownloadUtilizing Multiplex ddPCR to Streamline Viral Gene Therapy Workflows
Analytics play a pivotal role in their development and successful commercialization of gene therapies. For AAV-based therapies, DNA quantification techniques that can more precisely quantify viral genome titers are a must. In this white paper, discover how ddPCR provides a more rapid and robust approach to DNA quantification for gene therapies.
DownloadFlexible, phase-appropriate approach for gene therapies
Explore flexible, phase-appropriate viral vector solutions, from process and analytical development to commercial scale manufacturing. With robust platform approaches for AAV, integrated analytics and a global network, these capabilities help accelerate timelines, ensure quality, and support the unique needs of your cell or gene therapy program.
Download